Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- 12 VEGF Inhibitors Ordered to Add Artery Dissection Risk to ADR List
February 19, 2024
- Chugai’s PNH Med, Takeda’s cTTP Therapy Up for Advisory Panel Review on Feb. 29
February 16, 2024
- Japan Approves 1st Generics for 4 APIs towards June Listing, All See AGs
February 16, 2024
- Japan to Ponder New COVID Vaccine Composition from Spring
February 15, 2024
- Japan to Announce New Drug Prices on March 5
February 15, 2024
- AMED Chief Eyes 20-30% Team Expansion by FY2029
February 14, 2024
- Sawai and Kaigen Submit Biz Improvement Plans to Osaka Govt
February 14, 2024
- MHLW to Review Pig Kidney Transplant Plan Including Ethical Issues: Minister
February 14, 2024
- Chuikyo Issues 2024 Reform Recommendation; 1,000 Yen Premium Set for Inpatient Biosimilar Use
February 14, 2024
- Active Pharma Slapped with Biz Improvement Order for Illicit API Production
February 13, 2024
- MHLW Panel to Draw Up Report by Year-End towards Amendment of PMD Act
February 13, 2024
- Maintain Funding for COVID Pill beyond April: Academic Societies to Govt
February 13, 2024
- Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
February 13, 2024
- Japan to Allow Submissions without Japanese Data If All Requirements Met
February 9, 2024
- FPMAJ Supports Generic Industry Consortia Concept but Frets Antitrust Issues
February 9, 2024
- Health Minister Admits Antitrust Challenge in Generic Industry Revamp
February 9, 2024
- Takeda’s Acquired Hemophilia A Drug Up for Panel Review on February 22
February 9, 2024
- New Govt Forum Moots US-Level Trial Environment, Priority Review Vouchers
February 9, 2024
- Generic Panel to Issue Report in Spring-Summer to Drive Manufacturing Efficiency towards Stable Supplies: Official
February 8, 2024
- Japan to Revamp Scheme for Drug Maker’s Reporting of Supply Concerns in April
February 7, 2024
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…